Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13351MR)

This product GTTS-WQ13351MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13351MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13501MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ14MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ11250MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ14509MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ693MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ9867MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ7789MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ2746MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-139
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW